Abstract
BACKGROUND: Treatment of rosacea makes enough difficulties. Review of current etiology, pathogenesis and social burden of rosacea are presented, as well as results of international studies on efficacy of brimonidine gel (Mirvaso Derm) and ivermectin creme (Soolantra) usage in erytemato-teleangiectatic and papulopustular rosacea.
 AIMS: To evaluate efficacy and safety of topical ivermectin and brimonidine for the treatment of rosacea.
 MATERIALS AND METODS: Results of our own experience of using these drugs in 87 rosacea patients are presented. Depending on the subtype and severity of the disease, patients with erythematotelangiectatic subtype rosacea were treated with Mirvaso Derm gel (59%), Soolantra cream, and tacrolimus ointment (41%); doxycycline 0.10.2 g twice a day and Soolantra cream (29%); and minocycline 0.050.1 g a day and Soolantra cream (37%).
 Moreover, patients with papulopustular subtype rosacea were treated with the following combined therapy: doxycycline/minocycline + Mirvaso Derm gel + Soolantra cream (34%). Regardless of the severity of the process, all patients received Cetaphil Pro for redness prone skin (Cetaphil Redness Control line until 2018) as daily skin care products. The mean duration time of therapy for antibiotics was 1.52 month and topical therapy had a relatively longer duration time of therapy: from 8 to 24 months for Mirvaso Derm and 3 to 10 months for Soolantra.
 RESULTS: After the therapy 43 and 55% of patients with papulopustular rosacea achieved Investigator Global Assessment (IGA) scores of 0 (clear) and 1 (almost clear), respectively; and 41% and 50% of patients with erythemato-telangiectatic rosacea achieved IGA scores 0 and 1, respectively. During the 1-year follow-up clear and almost clear skin (IGA = 01) remained in 87% of patients with papulopustular subtype rosacea and 79% of patients with erythemato-telangiectatic subtype rosacea.
 CONCLUSION: Thus, based on the results, Mirvaso Derm gel and Soolantra creme have demonstrated to be very effective and safe options for rosacea treatment.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.